Recruiting

AeroPace System

Sponsor:

Lungpacer Medical Inc.

Code:

NCT07477054

Conditions

Ventilator Induced Diaphragm Dysfunction

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Lungpacer Diaphragm Pacing Therapy

Study Details

Brief summary:

A single-arm, prospective, multicenter cohort study to assess the 30-day continued safety and effectiveness of the AeroPace System in patients on mechanical ventilation (MV) at least 96 hours and who have not weaned. This is a study collecting real-world data in a post-market setting.

Conditions

Ventilator Induced Diaphragm Dysfunction

Study ID

NCT07477054

Start date

Oct 31, 2026

Status verified date

Oct, 2026

Completion date

Sep 30, 2028

Anticipated

Primary completion date

Aug 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Are 18 years or older, and,
2. Will have been mechanically ventilated for ≥96 hours (4 days) by the time of Catheter insertion, and,
3. Have not weaned from MV, and,
4. Have failed an institutional SBT within 48 hours of enrollment.

Exclusion Criteria:

1. Invasive mechanical ventilation >90 days.
2. Currently on extracorporeal membrane oxygenation (ECMO).
3. Weaning failure due to hypervolemia.
4. Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
5. Clinically overt congestive heart failure that is preventing weaning.
6. Currently being treated with neuromuscular blockade that could affect phrenic nerve / diaphragm contraction.
7. Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles.
8. Pre-existing severe chronic pulmonary fibrosis.
9. Known pleural effusions occupying greater than one third of the pleural space on either side.
10. BMI >70 kg/m2.
11. Known or suspected phrenic nerve paralysis.
12. Any electrical device (implanted or external) that may be prone to interaction with, or interference from the AeroPace System, including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators.
13. Current hemodynamic instability
14. Uncontrolled sepsis or septic shock.
15. Current or untreated bacteremia.
16. Expecting withdrawal of life support and/or shift to palliation as the goal of care.
17. Known or suspected to be pregnant or lactating.
18. Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.

Study Design

Enrollment

120 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Lungpacer AeroPace Therapy

Subject receives AeroPace therapy consisting of 60 stimulations, twice daily for a total of 120 stimulations/day, plus standard of care for weaning from mechanical ventilation including at least once daily spontaneous breathing trials.

Interventions

Lungpacer Diaphragm Pacing Therapy

Transvenous phrenic nerve stimulation to induce diaphragm contraction.

Primary outcome measure

  • Adverse Event Profile [ Time Frame: 30 days ]
  • Successful Weaning [ Time Frame: 30 days ]

Central Contacts and Locations

Central contacts

Locations

Sutter Health Research Institute

Recruiting

San Francisco, California, United States, 94109

Contacts

George Horng Principal Investigator, MD

415-923-3421clinicalresearch@sutterhealth.org

More Information

Sponsor

Lungpacer Medical Inc.

Last update posted

Oct 30, 2026

Last verified

Oct, 2026

Keywords

  • VIDD
  • Diaphragm Atrophy
  • Weaning Failure
  • SBT
  • Phrenic Nerve Stimulation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-31. This information was provided to ClinicalTrials.gov by Lungpacer Medical Inc. on 2026-10-30. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.